Short contact therapy with tazarotene in psoriasis vulgaris.
BACKGROUND
We present the results of a multicentre, not controlled, clinical study on the tolerability and efficacy of tazarotene gel, used as short contact therapy (SCT), in psoriasis vulgaris.


OBJECTIVE
To evaluate whether irritant contact dermatitis caused by tazarotene was less frequent and/or less severe with SCT than with traditional therapy, and whether SCT with tazarotene was as effective as traditional therapy.


METHODS
Forty-three patients with plaque psoriasis were treated by SCT with 0.1% tazarotene gel (once daily application for 20 min, followed by washing with water). Treatment duration was 45 days.


RESULTS
Irritant contact dermatitis caused by tazarotene used as SCT was much less frequent and severe than traditional treatment with the same drug. SCT with tazarotene was effective in the treatment of plaque psoriasis.


CONCLUSIONS
Tazarotene, used as SCT, was better tolerated than the same drug used as traditional treatment. Furthermore, SCT appeared to be as effective as traditional therapy with the same drug.
Veraldi
Stefano
S
Institute of Dermatological Sciences, IRCCS, University of Milan, Milan, Italy. stefano.veraldi@libero.it
Caputo
Ruggero
R
Pacifico
Alessia
A
Peris
Ketty
K
Soda
Rosario
R
Chimenti
Sergio
S
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D017453:Dermatitis, Irritant / Q000209:etiology / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy*; D012176:Retinoids / Q000008:administration & dosage / Q000009:adverse effects
D003879:Dermatologic Agents; D005782:Gels; D009539:Nicotinic Acids; D012176:Retinoids; C086827:tazarotene